Abstract:
This study sought to investigate the e cacy and safety of eribulin in advanced breast cancer patients. Eighteen patients with advanced breast cancer were retrospectively included. The previous use of taxanes, and the use of eribulin in subsequent treatment was reviewed. Progression- free survival PFS and the e cacy of eribulin, in uencing factors, and adverse reactions were analysed. For patients who were previously treated with taxanes were more resistant, subsequent eribulin treatment chemotherapy PFS was generally for two months. However, for patients who chose eribulin combined with anlotinib for the latter-line regimen, PFS reached for ve months, and these patients were in continuous remission. Among the 18 patients, 17 patients (94.4%) had di erent degrees of bone marrow suppression. Patients who have not been treated with taxanes or who have been treated with taxanes for a long response time, experience better e ects when eribulin was used as subsequent treatment. Eribulin combined with anlotinib is the preferred combination therapy.
Page(s):
122-124
DOI:
DOI not available
Published:
Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 1, Year: 2022
Keywords:
Safety
,
Breast Cancer
,
E cacy
,
Eribulin